Special Issue

Innovative Prophylactic and Therapeutics for the Treatment of Coronavirus Infection

Message from the Guest Editors

While COVID-19 is no longer a pandemic, a significant number of SARS-CoV-2 infections still occur around the world due to emerging viral variants. Massive vaccine campaigns initiated in early 2021 have saved millions of lives. More recently, antivirals have been used to therapeutically control SARS-CoV-2 infections. However, because viral variants are continuously emerging, including those with mutations that can escape immune responses induced by approved vaccines or the antiviral activity of antivirals, new prophylactic and/or therapeutic approaches are urgently needed to assure SARS-CoV-2 infection remains controlled. The concern that a new coronavirus could surface is ever present, and the development of new prophylactics/therapeutics is crucial to safeguard against potential future coronavirus pandemics. In this Special issue, we welcome submissions of original research, reviews, clinical trials, and opinion articles related to new prophylactic and therapeutic interventions for the treatment of SARS-CoV-2 and other coronavirus infections.

Guest Editors

Prof. Dr. Luis Martinez-Sobrido

Disease Prevention and Intervention Program, Texas Biomedical Research Institute, San Antonio, TX, USA

Prof. Dr. Jun-Gyu Park

Laboratory of Veterinary Zoonotic Diseases, College of Veterinary Medicine, Chonnam National University, Gwangju, Republic of Korea

Deadline for manuscript submissions

28 February 2026



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/226995

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

